Stockscreener 앱 받기
7.515
0.19%
-0.015
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
Entrada Therapeutics, Inc.(NasdaqGM: TRDA) dropped from Russell 2000 Defensive Index - marketscreener.com
Understanding Momentum Shifts in (TRDA) - Stock Traders Daily
Price to book forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to earnings forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Price to sales forward of Entrada Therapeutics, Inc. – NASDAQ:TRDA - TradingView
Entrada Therapeutics Inc Actuals & Estimates (NASDAQ:TRDA) - TradingView
TRDA Forecast — Price Target — Prediction for 2027 - TradingView
Entrada Therapeutics Inc (TRDA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Entrada Therapeutics Inc (TRDA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Entrada Therapeutics Inc (TRDA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Entrada Therapeutics Inc (TRDA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TRDA) Movement - Stock Traders Daily
Entrada Therapeutics Inc (TRDA) Institutional Confidence - TradingKey
Entrada Therapeutics Inc (TRDA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Entrada Therapeutics Inc (TRDA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Entrada Therapeutics Inc (TRDA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
[Form 4] Entrada Therapeutics, Inc. Insider Trading Activity - Stock Titan
Entrada Therapeutics (TRDA) awards director 19,000 options at $5.97 - Stock Titan
Entrada Therapeutics director granted 19,000 options | TRDA Insider Trading - Stock Titan
Entrada Therapeutics (TRDA) director receives 19,000-share stock option grant - Stock Titan
Entrada Therapeutics (TRDA) Gains Ground: Modest Rally Tests Key Resistance LevelsDay Trade Opportunities - newsline.com
Entrada Therapeutics Stockholders Approve Directors and Equity Plans - The Globe and Mail
[8-K] Entrada Therapeutics, Inc. Reports Material Event - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE) - The Globe and Mail
Entrada Therapeutics Inc. (TRDA) Q1 2026 Earnings: Narrower Loss Surprises, but No Revenue Weighs on SharesROIC Trend Report - newsline.com
Entrada Therapeutics (TRDA) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary - Quartr
Entrada Therapeutics Inc. (TRDA) Faces Selling Pressure as Shares Dip to $6.20Triple Top - dars.gov.et
Discipline and Rules-Based Execution in TRDA Response - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
TRDA: Strong safety and early efficacy in DMD trials drive confidence in a growing clinical pipeline - TradingView
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Safety committee approves higher 10 mg/kg dose for Entrada's Duchenne muscular dystrophy trial - Pluang
Entrada gets clearance to escalate dose in DMD trial By Investing.com - Investing.com South Africa
Entrada gets clearance to escalate dose in DMD trial - Investing.com
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study - The Manila Times
Rare disease trial tests DMD treatment with once-every-six-week dosing - Stock Titan
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-05-27 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Entrada Therapeutics, Inc. (TRDA) And Encourages Shareholders to Reach Out | NDAQ:TRDA | Press Release - Stockhouse
Behavioral Patterns of TRDA and Institutional Flows - Stock Traders Daily
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDAEntrada Therapeutics Inc Stock Price and Quote - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com India
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
1.95%
2.70%
자본화:
|
볼륨(24시간):